Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-17
2006-01-17
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S336000, C514S340000
Reexamination Certificate
active
06987121
ABSTRACT:
Methods for the treatment of cholestatic liver disease and reduction and prevention of hepatic injury resulting from cholestasis via administration of a FXR ligand are provided.
REFERENCES:
patent: 6187814 (2001-02-01), Elias et al.
patent: 2003/0130296 (2003-07-01), Bauer et al.
patent: WO 00/25134 (2000-05-01), None
patent: WO 00/37077 (2000-06-01), None
patent: WO 00/37077 (2000-06-01), None
patent: WO 00/57915 (2000-10-01), None
patent: WO 02/24632 (2002-03-01), None
patent: WO 02/020463 (2002-03-01), None
patent: WO 02/072598 (2002-09-01), None
patent: WO 03/015771 (2003-02-01), None
patent: WO 03/015777 (2003-02-01), None
patent: WO 03/016280 (2003-02-01), None
patent: WO 03/016288 (2003-02-01), None
patent: WO 03/042400 (2003-06-01), None
patent: WO 03/060078 (2003-07-01), None
Willson, T. M. et al., Chemical Genomics: Functional Analysis of Orphan Nuclear Receptors in the Regulation of Bile Acid Metabolism, Medicinal Research Reviews, vol. 21, No. 6, 513-522, 2001.
Willson T. M. et al., “Chemical genomics: Functional analysis of orphan nuclear recetprors in the regulation of bile acid metabolism”, Abstract to Medicinal Research Reviews, 21(6), Nov. 2001, pp 513-522.
Howard et al., “Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor,”Toxicology and Applied Pharmacology163:195-202 (2000).
Beuers et al., “Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications,”Hepatology28(6):1449-1453 (1998).
Goodwin et al., “A regulatory cascade of the nuclear receptors FXR, SJP-1, and LRH-1 represses bile acid biosynthesis,”Molecular Cell6:517-526 (Sep. 2000).
Greve et al., “Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: An in vitro study,”Hepatology10(4):454-458 (1989).
Grober et al., “Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene,”The Journal of Biological Chemistry274(42):29749-29754 (Oct. 1999).
Hofmann, “The continuing importance of bile acids in liver and intestinal disease,”Arch Intern Med159:2647-2658 (Dec. 1999).
Karpen, “Bile acids go nuclear!,”Hepatology30(4):1107-1109 (Oct. 1999).
Kerr et al., “Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis,”Development Cell2:713-720 (Jun. 2002).
Kumar et al., “Use of ursodeoxycholic acid in liver diseases,”Journal of Gastroenterology and Hepatology16:3-14 (2001).
Leuschner et al., “Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial,”Gastroenterology97:1268-1274 (1989).
Lu et al., “Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors,”Molecular Cell6:507-515 (2000).
Lu et al., “Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism,”The Journal of Biological Chemistry276(41):37735-37738 (Oct. 2001).
Makishima et al., “Identification of a nuclear receptor for bile acids,”Science284:1362-1365 (May 1999).
Maloney et al., “Identification of a chemical tool for the orphan nuclear receptor FXR,”Journal of Medicinal Chemistry43(16):2971-2974 (Aug. 2000).
Parks et al., “Bile acids: natural ligands for an orphan nuclear receptor,”Science284:1365-1368 (May 1999).
Podda et al., “Ursodeoxycholic acid for chronic liver diseases,”J. Clin. Gastroenterol.10(Suppl 2):S25-S31 (1988).
Poupon et al., “Ursodeoxycholic acid therapy of chronic cholestatic conditions in aduls and children,”Pharmac. Ther.66:1-15 (1995).
Sinal et al., “Targeted disruption of the nuclear receptor FXR/BAR Impairs bile acid and lipid homeostasis,”Cell102:731-744 (Sep. 2000).
Wang et al., “Endogenous bile acids are ligands for the nuclear receptor FXR/BAR,”Molecular Cell3:543-553 (May 1999).
Willson et al., “Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism,”Medicinal Research Reviews21(6):513-522 (2001).
Ananthanarayanan et al., “Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor,”The Journal of Biological Chemistry276(31):28857-28865 (Aug. 2001).
Arrese et al., “New horizons in the regulation of bile acid and lipid homeostasis: critical role of the nuclear receptor FXR as an intracellular bile acid sensor,”GUT49:465-466 (2001).
Forman et al., “Identification of a nuclear receptor that is activated by farnesol metabolites,”Cell81:687-693 (Jun. 1995).
Goulis et al., “Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis,”The Lancet354:1053-1060 (Sep. 1999).
Fiorucci et al., “A novel and potent FXR agonist inhibits endogenous bile acids synthesis and protects against cholestasis,”Gastroenterology122(4)(Suppl 1):A-444 (Abstract T1262) (Apr. 2002) (Abstracts from the 103rdAnnual Meeting of the American Gastroenterological Association, May 19-22, 2002, San Francisco, CA).
Suwannaroj et al., “Suppression of renal disease and mortality in the female NZBxNZW F1mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid,”Lupus10:562-567 (2001).
Denson et al., The Orphan Nuclear Receptor, shp, Mediates Bile Acid-Induced Inhibition of the Rat Bile Acid Transporter, ntcp, Gastroenterology 121:140-147 (2001).
Kliewer Steven Anthony
Mansfield Traci
Willson Timothy Mark
Campen Virginia G.
Jones Dwayne
SmithKline Beecham Corporation
LandOfFree
Compositions and methods for hepatoprotection and treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for hepatoprotection and treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for hepatoprotection and treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3544036